Companies › Sichuan Huiyu Pharmaceutical
8 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 4, 1 Phase 3, 1 Phase 2; Oncology, Other, Hematology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HY-2003 Injection for reduction of submental fat accumulation | – | Phase 1 | Moderate or Severe Submental Fullness | Dec 2026 |
| HYP-2090PTSA KRAS G12C inhibitor | KRAS | Phase 1 | Safety | Dec 2026 |
| Ferric Carboxymaltose Injection Iron replacement therapy; ferric iron complexed with carboxymaltose | – | Phase 1 | Healthy Adult; Postpartum Depression (PPD); Pulmonary Hypertension; Aortic Valve Stenosis … | Jan 2027 |
| HY07121 | – | Phase 1 | Safety | May 2027 |
| HY0001a for injection | – | Phase 1 | Solid Tumor | Jun 2027 |
| HY05350 anti-MSLN antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumor | Mar 2028 |
| HYP-6589 EGFR kinase inhibitor | – | Phase 1 | Solid Tumor | Apr 2028 |
| Ferric Derisomaltose Injection Iron supplement - ferric ion delivered via derisomaltose complex | – | Phase 1 | Iron Deficiency Anemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07790562 | Ferric Derisomaltose Injection | Phase 1 | Iron Deficiency Anemia | Hematology | Sep 2026 |
| NCT06756490 | HY-2003 | Phase 1 | Moderate or Severe Submental Fullness | Oncology | Dec 2026 |
| NCT06243354 | HYP-2090PTSA | Phase 1 | Safety | Other | Dec 2026 |
| NCT07606105 | Ferric Carboxymaltose Injection | Phase 1 | Healthy Adult | Other | Jan 2027 |
| NCT06639256 | HY07121 | Phase 1 | Safety | Other | May 2027 |
| NCT07069062 | HY0001a for injection | Phase 1 | Solid Tumor | Oncology | Jun 2027 |
| NCT07217873 | Ferric Carboxymaltose Injection | Phase 2 | Scoliosis Correction | Hematology | Aug 2027 |
| NCT05744219 | Ferric Carboxymaltose Injection | Phase 3 | Surgery | Oncology | Dec 2027 |
| NCT07083323 | HY05350 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2028 |
| NCT06712680 | HYP-6589 | Phase 1 | Solid Tumor | Oncology | Apr 2028 |
| NCT06833788 | Ferric Carboxymaltose Injection | Phase 4 | Postpartum Depression (PPD) | Psychiatry | Jun 2028 |
| NCT07359599 | Ferric Carboxymaltose Injection | Phase 4 | Pulmonary Hypertension | Cardiovascular | Jul 2028 |
| NCT07370688 | Ferric Carboxymaltose Injection | Phase 4 | Aortic Valve Stenosis | Cardiovascular | Jul 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.